197 related articles for article (PubMed ID: 33882406)
1. Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
Miller HA; Yin X; Smith SA; Hu X; Zhang X; Yan J; Miller DM; van Berkel VH; Frieboes HB
Lung Cancer; 2021 Jun; 156():20-30. PubMed ID: 33882406
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Lung Cancer Patient Response to First-Line Chemotherapy by Integration of Tumor Core Biopsy Metabolomics with Multiscale Modeling.
Miller HA; Miller DM; van Berkel VH; Frieboes HB
Ann Biomed Eng; 2023 Apr; 51(4):820-832. PubMed ID: 36224485
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer survival prediction and biomarker identification with an ensemble machine learning analysis of tumor core biopsy metabolomic data.
Miller HA; van Berkel VH; Frieboes HB
Metabolomics; 2022 Jul; 18(8):57. PubMed ID: 35857204
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer metabolomic data from tumor core biopsies enables risk-score calculation for progression-free and overall survival.
Miller HA; Rai SN; Yin X; Zhang X; Chesney JA; van Berkel VH; Frieboes HB
Metabolomics; 2022 May; 18(5):31. PubMed ID: 35567637
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic Profiling.
Tian Y; Wang Z; Liu X; Duan J; Feng G; Yin Y; Gu J; Chen Z; Gao S; Bai H; Wan R; Jiang J; Liu J; Zhang C; Wang D; Han J; Zhang X; Cai L; He J; Wang J
Clin Cancer Res; 2018 May; 24(9):2100-2109. PubMed ID: 29437793
[No Abstract] [Full Text] [Related]
6. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
7. Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer.
Han M; Liu Q; Yu J; Zheng S
Clin Chem Lab Med; 2010 Jun; 48(6):863-7. PubMed ID: 20345233
[TBL] [Abstract][Full Text] [Related]
8. Primal-dual for classification with rejection (PD-CR): a novel method for classification and feature selection-an application in metabolomics studies.
Chardin D; Humbert O; Bailleux C; Burel-Vandenbos F; Rigau V; Pourcher T; Barlaud M
BMC Bioinformatics; 2021 Dec; 22(1):594. PubMed ID: 34911437
[TBL] [Abstract][Full Text] [Related]
9. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.
Peng J; Zou D; Han L; Yin Z; Hu X
Front Immunol; 2021; 12():778276. PubMed ID: 35095850
[TBL] [Abstract][Full Text] [Related]
10. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the Akt pathway.
Zheng J; Zheng Y; Li W; Zhi J; Huang X; Zhu W; Liu Z; Gong L
Clin Chim Acta; 2022 May; 530():66-73. PubMed ID: 35245482
[TBL] [Abstract][Full Text] [Related]
11. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
Zhang Y; Cheng Y; Qin L; Liu Y; Huang S; Dai L; Tao J; Pan J; Su C; Zhang Y
Int J Biol Markers; 2023 Mar; 38(1):37-45. PubMed ID: 36377344
[TBL] [Abstract][Full Text] [Related]
12. [Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Zhao G; Xu B; Li X; Tang C; Qin H; Wang H; Yang S; Wang W; Gao H; He K; Liu X
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):318-325. PubMed ID: 28532539
[TBL] [Abstract][Full Text] [Related]
13. Integration of metabolomics and machine learning revealed tryptophan metabolites are sensitive biomarkers of pemetrexed efficacy in non-small cell lung cancer.
Sun R; Fei F; Wang M; Jiang J; Yang G; Yang N; Jin D; Xu Z; Cao B; Li J
Cancer Med; 2023 Sep; 12(18):19245-19259. PubMed ID: 37605514
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
15. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Imamura F; Minamikawa K; Takano T; Kobayashi H
Lung Cancer; 2010 Jun; 68(3):472-7. PubMed ID: 19660825
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of the generalised predictive ability of eight machine learning algorithms across ten clinical metabolomics data sets for binary classification.
Mendez KM; Reinke SN; Broadhurst DI
Metabolomics; 2019 Nov; 15(12):150. PubMed ID: 31728648
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic biomarkers in cervicovaginal fluid for detecting endometrial cancer through nuclear magnetic resonance spectroscopy.
Cheng SC; Chen K; Chiu CY; Lu KY; Lu HY; Chiang MH; Tsai CK; Lo CJ; Cheng ML; Chang TC; Lin G
Metabolomics; 2019 Oct; 15(11):146. PubMed ID: 31664624
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
19. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
